MARSH & MCLENNAN COMPANIES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $MRSH in the last 30 days.
See all $MRSH insider activity →L1 Capital International Fund exited its position in Marsh & McLennan Companies (MRSH) during Q3 2026, citing challenging cyclical conditions in insurance markets. The fund views MRSH as well-managed but redeployed capital into more compelling opportunities. MRSH closed at $191.26 on October 20, 2026, with a market cap of $90.95 billion and a 3.09% YTD gain.
Marsh (MRSH) priced €1.2 billion in senior notes: €600M at 4.250% due 2032 and €600M at 4.625% due 2036. Proceeds for general corporate purposes. Closing expected October 27, 2026. Joint book-runners include Merrill Lynch, Deutsche Bank, and Barclays. Marsh has $27B annual revenue and 95,000 employees.
Keefe Bruyette & Woods raised its price target for Marsh & McLennan (NYSE: MRSH) to $201 from $186, citing adjusted earnings estimates. The firm lowered 2027 and 2028 EPS estimates but expects faster organic growth in consulting. Marsh reported Q2 EPS of $2.96, beating estimates, and revenue of $7.4B, exceeding expectations. Mizuho also raised its target to $201, while BMO Capital maintained a $203 target.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning MRSH (MARSH & MCLENNAN COMPANIES, INC.). Coverage has skewed bullish: 1 bullish, 4 neutral, and 0 bearish.
Recent MRSH coverage spans financial news, earnings and corporate actions.
The fund's exit may signal short‑term weakness for MRSH as a sizable holder sold at a perceived fair‑value level.
New senior‑note issuance adds debt and may modestly weigh on equity price.
Analyst upgrade signals confidence in Marsh's earnings and outlook.
Strong results boost confidence in insurers.
The slight target increase may generate modest buying interest, but the Neutral rating limits upside.
AlphAI scores every news story that mentions MRSH with an AI model for sentiment and relevance, and aggregates insider trades from MARSH & MCLENNAN COMPANIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
L1 Capital International Fund exited its position in Marsh & McLennan Companies (MRSH) during Q3 2026, citing challenging cyclical conditions in insurance markets. The fund views MRSH as well-managed but redeployed capital into more compelling opportunities. MRSH closed at $191.26 on October 20, 2026, with a market cap of $90.95 billion and a 3.09% YTD gain.
1 min readMarsh (MRSH) priced €1.2 billion in senior notes: €600M at 4.250% due 2032 and €600M at 4.625% due 2036. Proceeds for general corporate purposes. Closing expected October 27, 2026. Joint book-runners include Merrill Lynch, Deutsche Bank, and Barclays. Marsh has $27B annual revenue and 95,000 employees.
2 min readKeefe Bruyette & Woods raised its price target for Marsh & McLennan (NYSE: MRSH) to $201 from $186, citing adjusted earnings estimates. The firm lowered 2027 and 2028 EPS estimates but expects faster organic growth in consulting. Marsh reported Q2 EPS of $2.96, beating estimates, and revenue of $7.4B, exceeding expectations. Mizuho also raised its target to $201, while BMO Capital maintained a $203 target.
2 min readWall Street closed mixed, with TD Bank, Mastercard, and Visa gaining, while Bank of America, Morgan Stanley, and Citigroup declined. TransUnion rose 13.13% after a deal with Bankrate. IREN fell 23.30% despite a cloud deal. Insurance stocks advanced on strong earnings.
3 min readCitigroup maintained a Neutral rating on Marsh (MRSH) and raised its price target from $200 to $203. Marsh is trading at $188.35, which is 26.2% undervalued compared to its GF Value™ of $255.35. The company has a GF Score™ of 84/100, reflecting strong profitability and growth. 13 gurus hold MRSH, with mixed activity in recent quarters.
2 min readWells Fargo maintained an Equal-Weight rating on Marsh (MRSH) and raised its price target to $197 from $183. GuruFocus values MRSH at $255.35, suggesting a 26.7% undervaluation. The company has a GF Score of 84/100, with strong profitability and growth but low momentum. Insiders have sold $8.21M in shares over the past three months.
1 min readMarsh McLennan (MRSH) rose 6.31% to $189.66 after U.S. PPI data exceeded expectations, benefiting inflation-sensitive stocks. MRSH's gain was also driven by strong earnings. Comparatively, Brown & Brown (BRO) and Murphy USA (MUSA) rose 5.90% and 1.87%, respectively. Investors should note MRSH's performance includes both inflation and company-specific catalysts.
2 min readMARSH & MCLENNAN COMPANIES, INC. (MRSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Marsh 212 345 5000 www.marsh.com News release Exhibit 99.1 Marsh reports third quarter 2026 results • Revenue Growth of 8%; Underlying Revenue Growth of 5% • GAAP Operating Income Increases 4%; Adjusted Operating Income Increases 6% • Third Quarter GAAP EPS of $1.69; Adjusted EPS
2 min readMarsh & McLennan (MMC) shares rose 7% after Q3 earnings and revenue beat estimates. Adjusted EPS was $2.03 vs. $1.96 expected, up 10% YoY. Revenue grew 8% to $6.86B, driven by risk services and consulting. Risk division revenue increased 10% to $3.73B, while consulting revenue rose 9% to $2.7B. Operating income grew 6% adjusted, 4% reported.
2 min readCongressman Kevin Hern sold shares in Chevron (CVX), Chubb (CB), Devon Energy (DVN), and other companies, according to a congressional trade report. Chevron shares are up 47% year-to-date, with a 3.27% dividend yield and a P/E ratio of 21.34. Analysts have revised earnings upwards for the company. Hern also bought government securities.
2 min read
